Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Lancet. Rheumatology|March 23, 2021
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trialPaul C Cremer, Antonio Abbate, Kristin Hudock, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 1, 2006
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjectsE M Migoya, A Bergman, D Hreniuk, et al.
Expert Review of Vaccines|April 12, 2016
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesP Vici, L Pizzuti, L Mariani, et al.
Journal of Lipid Research|January 7, 2015
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHARuud S Kootte, Loek P Smits, Fleur M van der Valk, et al.
The Lancet. Rheumatology|August 25, 2020
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort studyGiacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
The Lancet. Neurology|March 10, 2012
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFGraeme J Hankey, Manesh R Patel, Susanna R Stevens, et al.
Lancet (London, England)|July 2, 2023
Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case reportMuhammad M Mohiuddin, Avneesh K Singh, Linda Scobie, et al.
Pageof 10